The latest announcement is out from Abeona Therapeutics (ABEO).
At the recent virtual Annual Meeting, shareholders elected Leila Alland and Vishwas Seshadri as Class 2 directors until the 2027 annual meeting. Additionally, a proposal to double the number of shares reserved for issuance was approved, as was the advisory vote on executive compensation. The appointment of Deloitte & Touche LLP as the independent accounting firm for the upcoming fiscal year was also ratified, reflecting a proactive and forward-looking approach to corporate governance and financial planning by the company’s stakeholders.
See more insights into ABEO stock on TipRanks’ Stock Analysis page.
